Business Wire

TX-PANDA-BIOTECH

3.4.2024 15:01:28 CEST | Business Wire | Press release

Share
Panda Biotech Announces Commercial Operations Have Begun at Its Flagship Panda Hemp Gin

Panda Biotech™ announced today that commercial operations have officially begun at the Panda Hemp Gin, their landmark industrial hemp processing facility in Wichita Falls, Texas. The 500,000-square-foot building situated on 97 acres is the first of its kind and the largest in the Western Hemisphere, with the capacity to process 10 metric tons of industrial hemp into textile-grade fiber, hurd, short-fiber/hurd mix, and nutrient-rich micronized hurd per hour. It is a zero-waste process, utilizing every part of the industrial hemp stalk, and operates solely on 100 percent renewable energy, making it a paragon of sustainability in the industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403426324/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Panda Hemp Gin is a 500,000-square-foot building situated on 97 acres with the capacity to process 10 metric tons of industrial hemp into textile-grade fiber, hurd, short-fiber/hurd mix, and nutrient-rich micronized hurd per hour. (Photo: Business Wire)

The Panda Hemp Gin is fully operational, and production will continue to ramp up in the coming months. In February, the complex commissioning process of Panda's 600-yard-long processing line and three miles of overhead pneumatic duct lines, including each piece of equipment for decortication, refining, blending, mechanical cottonization, hurd bagging and storage, and baling, was successfully completed.

"Panda Biotech's state-of-the-art industrial hemp processing facility is a monumental achievement and a game-changer for both agriculture and industry,” said Dixie Carter, president of Panda Biotech. “As research and development in this area continue to advance, industrial hemp fiber and cellulose will help transform numerous industries with sustainable goals and challenges. Panda’s industrial hemp will play a pivotal role in satisfying significant global market demand for renewable processes and products.”

Industrial hemp is considered one of the most versatile raw materials available with an unmatched variety of potential uses. The Panda Hemp Gin will focus on providing five main product lines from hemp, including mechanically cottonized fiber, decorticated fiber, hurd (cellulose), short-fiber/hurd mix, and nutrient-rich micronized hemp dust. The innumerous applications for each product vary broadly from consumer and industrial textiles, non-wovens, paper products, bioplastics, biofuel, animal bedding, fiberglass substitute, construction materials such as hempcrete, mulch, insulation, and more.

With a commitment to traceability and processing only U.S.-grown hemp straw, as well as providing an astounding pay-to-grow program, Panda’s partnership with the American farming community is at the heart of the operation. Industrial hemp provides a multitude of benefits for producers, as it is scientifically proven to minimize CO2 emissions, absorbing more per acre than any forest or commercial crop. Additionally, hemp requires significantly less water than most major crops, provides outstanding soil remediation, and requires minimal fertilizers, pesticides, and herbicides. Panda is actively contracting with producers for its pay-to-grow program for this harvest and with farmers who may have straw or fiber from previous harvests or the 2024 growing season. Interested producers can reach out to Panda through the website at pandabiotech.com.

"The massive scale of the campus, allowing more than 22,000 pounds of baled hemp straw for processing per hour, is what makes this industrial hemp processing facility unique,” said Scott Evans, chief operating officer of Panda Biotech. “Our straw is sourced directly from our farming partners in Texas and surrounding states, and, through our decortication process, it is transformed into packaged products, ready for retail or downstream manufacturing applications, within minutes. Panda's processing equipment and infrastructure is truly best-in-class."

For more information, please visit www.pandabiotech.com and follow us at @pandabiotech on Facebook, Instagram, X, and LinkedIn.

ABOUT PANDA BIOTECH

Based in Dallas, Texas, privately-held Panda Biotech, LLC is a first-mover in the emerging U.S. industrial hemp fiber and hurd industry that is 100 percent American-owned, grown, and processed. Panda Biotech’s executive leadership has extensive experience developing, financing, constructing, and operating large-scale infrastructure facilities in clean energy. They have developed 22 projects representing approximately $12 billion in invested capital. Panda Biotech’s first project, the Panda Hemp Gin™, is in partnership with Aka-Ag, LLC, a wholly-owned subsidiary of the Southern Ute Indian Tribe Growth Fund. The facility is located in Wichita Falls, Texas. It is the largest industrial hemp processing facility of its kind in the Western Hemisphere.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240403426324/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye